Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis

British Journal of Pharmacology

Volumn 170, Issue 3, 2013, Pages 602-613

  Gonzalez Garcia C ^a,c   Bravo, B ^a   Ballester, A ^a   Gomez Perez R ^a,d   Eguiluz, C ^a   Redondo, M ^b   Martinez A ^b   Gil, C ^b   Ballester, S ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

EAE; inflammation; inhibitor; PDE

Indexed keywords

2 METHYL 5 NITROBENZENESULFONIC ACID DIMETHYLAMIDE; COMPOUND TC 3.6; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 27; INTERLEUKIN 4; MESSENGER RNA; PHOSPHODIESTERASE VII INHIBITOR; ROLIPRAM; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY INFILTRATE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN CELL;

EAE; INFLAMMATION; INHIBITOR; PDE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; CELLS, CULTURED; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 7; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FORKHEAD TRANSCRIPTION FACTORS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKINS; MICE; MICE, INBRED C57BL; PHOSPHODIESTERASE 4 INHIBITORS; ROLIPRAM; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 84884535469     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12308     Document Type: Article

References (53)

1. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, et al. (2010). T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16: 406-412.
2. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, et al. (2006). Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 7: 929-936.
3. Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA, Kuchroo VK, (1998). IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol 161: 3299-3306.
4. Bettelli E, Nicholson LB, Kuchroo VK, (2003). IL-10, a key effector regulatory cytokine in experimental autoimmune encephalomyelitis. J Autoimmun 20: 265-267.
5. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. (2006). Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
6. Blaszczyk B, Gieldanowski J, Karakoz I, (1978). Experimental allergic encephalomyelitis in chickens. Arch Immunol Ther Exp (Warsz) 26: 743-746.
7. Brudvik KW, Tasken K, (2012). Modulation of T cell immune functions by the prostaglandin E(2)-cAMP pathway in chronic inflammatory states. Br J Pharmacol 166: 411-419.
8. Castano T, Wang H, Campillo NE, Ballester S, Gonzalez-Garcia C, Hernandez J, et al. (2009). Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors. ChemMedChem 4: 866-876.
9. Chen SJ, Wang YL, Fan HC, Lo WT, Wang CC, Sytwu HK, (2012). Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. Clin Dev Immunol 2012: 970789: 1-16.
10. Click RE, Benck L, Alter BJ, (1972). Enhancement of antibody synthesis in vitro by mercaptoethanol. Cell Immunol 3: 156-160.
11. Constantinescu CS, Farooqi N, O'Brien K, Gran B, (2011). Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 164: 1079-1106.
12. Correa JO, Aarestrup BJ, Aarestrup FM, (2010). Effect of thalidomide and pentoxifylline on experimental autoimmune encephalomyelitis (EAE). Exp Neurol 226: 15-23.
13. Diveu C, McGeachy MJ, Boniface K, Stumhofer JS, Sathe M, Joyce-Shaikh B, et al. (2009). IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol 182: 5748-5756.
14. Ehirchiou D, Xiong Y, Xu G, Chen W, Shi Y, Zhang L, (2007). CD11b facilitates the development of peripheral tolerance by suppressing Th17 differentiation. J Exp Med 204: 1519-1524.
15. Falcone M, Rajan AJ, Bloom BR, Brosnan CF, (1998). A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. J Immunol 160: 4822-4830.
16. Fitzgerald DC, Ciric B, Touil T, Harle H, Grammatikopolou J, Das Sarma J, et al. (2007a). Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J Immunol 179: 3268-3275.
17. Fitzgerald DC, Zhang GX, El-Behi M, Fonseca-Kelly Z, Li H, Yu S, et al. (2007b). Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 8: 1372-1379.
18. Genain CP, Roberts T, Davis RL, Nguyen MH, Uccelli A, Faulds D, et al. (1995). Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci U S A 92: 3601-3605.
19. Giembycz MA, Smith SJ, (2006). Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? Curr Pharm Des 12: 3207-3220.
20. Inoue M, Williams KL, Oliver T, Vandenabeele P, Rajan JV, Miao EA, et al. (2012). Interferon-beta therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci Signal 5: ra38.
21. Jerez MJ, Jerez M, González-García C, Ballester S, Castro A, (2013). Combined use of pharmacophoric models together with drug metabolism and genotoxicity ' 'in silico' ' studies in the hit finding process. J Comput Aided Mol Des 27: 79-90.
22. Kambayashi T, Wallin RP, Ljunggren HG, (2001). cAMP-elevating agents suppress dendritic cell function. J Leukoc Biol 70: 903-910.
23. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
24. Kohm AP, Carpentier PA, Miller SD, (2003). Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4+CD25+ regulatory T cells. Novartis Found Symp 252: 45-52. discussion 52-44, 106-114.
25. McGeachy MJ, Stephens LA, Anderton SM, (2005). Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 175: 3025-3032.
26. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
27. Martinez I, Puerta C, Redondo C, Garcia-Merino A, (1999). Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase. J Neurol Sci 164: 13-23.
28. Martin-Saavedra FM, Flores N, Dorado B, Eguiluz C, Bravo B, Garcia-Merino A, et al. (2007). Beta-interferon unbalances the peripheral T cell proinflammatory response in experimental autoimmune encephalomyelitis. Mol Immunol 44: 3597-3607.
29. Martin-Saavedra FM, Gonzalez-Garcia C, Bravo B, Ballester S, (2008). Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol 45: 4008-4019.
30. Medina-Rodríguez EM, Arenzana EJ, Pastor J, Redondo M, Palomo V, García de Sola R, et al. (2013). Inhibition of endegenous Phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cell Mol Life Sci (in press).
31. Mosenden R, Tasken K, (2011). Cyclic AMP-mediated immune regulation-overview of mechanisms of action in T cells. Cell Signal 23: 1009-1016.
32. Mosman T, (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
33. Murugaiyan G, Mittal A, Lopez-Diego R, Maier LM, Anderson DE, Weiner HL, (2009). IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol 183: 2435-2443.
34. O'Connor RA, Anderton SM, (2008). Foxp3+ regulatory T cells in the control of experimental CNS autoimmune disease. J Neuroimmunol 193: 1-11.
35. Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK, (2009). Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 57: 182-193.
36. Pfaffl MW, (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
37. Pierson E, Simmons SB, Castelli L, Goverman JM, (2012). Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol Rev 248: 205-215.
38. Portolés P, Rojo J, Golby A, Bonneville M, Gromkowski S, Greenbaum L, et al. (1989). Monoclonal antibodies to murine CD3ε define distinct epitopes, one of which may interact with CD4 during T cell activation. J Immunol 142: 4169-4175.
39. Reder AT, Thapar M, Sapugay AM, Jensen MA, (1994). Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuroimmunol 54: 117-127.
40. Redondo M, Brea J, Perez DI, Soteras I, Val C, Perez C, et al. (2012a). Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. J Med Chem 55: 3274-3284.
41. Redondo M, Palomo V, Brea J, Perez DI, Martin-Alvarez R, Perez C, et al. (2012b). Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice. ACS Chem Neurosci 3: 793-803.
42. Redondo M, Zarruk JG, Ceballos P, Perez DI, Perez C, Perez-Castillo A, et al. (2012c). Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. Eur J Med Chem 47: 175-185.
43. Ross SE, Williams RO, Mason LJ, Mauri C, Marinova-Mutafchieva L, Malfait AM, et al. (1997). Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 159: 6253-6259.
44. Sanchez AJ, Puerta C, Ballester S, Gonzalez P, Arriaga A, Garcia-Merino A, (2005). Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. J Neuroimmunol 168: 13-20.
45. Selvaraj RK, Geiger TL, (2008). Mitigation of experimental allergic encephalomyelitis by TGF-beta induced Foxp3+ regulatory T lymphocytes through the induction of anergy and infectious tolerance. J Immunol 180: 2830-2838.
46. Shevach EM, (2009). Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30: 636-645.
47. Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, et al. (2004). Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl- nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 66: 1679-1689.
48. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, et al. (1995). The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1: 244-248.
49. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, et al. (2006). Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 7: 937-945.
50. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M, (1971). Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1: 242-248.
51. Valaperti A, Marty RR, Kania G, Germano D, Mauermann N, Dirnhofer S, et al. (2008). CD11b+ monocytes abrogate Th17 CD4+ T cell-mediated experimental autoimmune myocarditis. J Immunol 180: 2686-2695.
52. Wang J, Wang G, Sun B, Li H, Mu L, Wang Q, et al. (2008). Interleukin-27 suppresses experimental autoimmune encephalomyelitis during bone marrow stromal cell treatment. J Autoimmun 30: 222-229.
53. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N, (1992). Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356: 63-66.